Scarica l'app Stockscreener
1.13
4.63%
0.05
Pre-mercato:
1.15
0.02
+1.77%
Conduit Pharmaceuticals Inc Borsa (CDT) Ultime notizie
Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now? - Insider Monkey
Conduit Pharmaceuticals Gets Nasdaq Extension, Plans Capital Market Transfer -March 06, 2025 at 10:42 am EST - Marketscreener.com
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel - The Manila Times
Conduit Pharmaceuticals secures Nasdaq extension - Investing.com
Conduit Pharmaceuticals Secures Extension for Nasdaq Compliance Following Bid Price Regaining - Nasdaq
Conduit Pharmaceuticals secures Nasdaq extension By Investing.com - Investing.com Australia
Conduit Pharmaceuticals Inc (NASDAQ: CDT) Is Down -83.09% So Far This Year: What Will Happen Next? - Stocks Register
Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Update - Defense World
Taking a look at what insiders are doing to gauge the Conduit Pharmaceuticals Inc (CDT)’s direction - Knox Daily
Conduit Pharmaceuticals Advances Phase II AI Collaboration With Sarborg To Enhance Drug Development - Nasdaq
Conduit Progresses Phase II of its AI Initiative with Sarborg - The Manila Times
How Conduit's New AI System Could Revolutionize Drug Development Decision-Making - StockTitan
Conduit Pharmaceuticals acts to regain Nasdaq compliance By Investing.com - Investing.com South Africa
Conduit Pharmaceuticals acts to regain Nasdaq compliance - Investing.com India
Conduit Pharmaceuticals Files For Offering Of Up To $17.8 Million Of Shares Of Common StockSEC Filing - Marketscreener.com
Understanding the Risks of Investing in Conduit Pharmaceuticals Inc (CDT) - Knox Daily
Conduit Pharmaceuticals to execute 1-for-100 reverse stock split - MSN
Conduit Pharmaceuticals enacts reverse stock split to meet Nasdaq standards - MSN
Conduit Pharmaceuticals, Charles River Laboratories Partner to Evaluate Potential Lupus Treatment - Marketscreener.com
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model - The Manila Times
Major Lupus Breakthrough? Conduit Teams Up with Charles River for Game-Changing Treatment Study - StockTitan
Weekly TechBio News 🤹 - substack.com
Conduit Pharmaceuticals announces debt repayment and partial conversion of senior secured note - MSN
Small Cap Stocks To Watch NowFebruary 09th - MarketBeat
Promising Small Cap Stocks To Keep An Eye OnFebruary 07th - MarketBeat
Conduit Pharmaceuticals settles debt, converts senior note - MSN
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note - The Manila Times
Conduit Pharmaceuticals settles debt, converts senior note By Investing.com - Investing.com Australia
What is Conduit Pharmaceuticals Inc (CDT) Stock Return on Shareholders’ Capital? - SETE News
Conduit, MGO Global, and Cyclo Therapeutics: Penny Stocks to Watch This Week - PUNE.NEWS
3 Penny Stocks to Watch Now, 2/11/25 - TipRanks
Conduit Pharmaceuticals Inc [CDT] is -58.45% lower this YTD. Is it still time to buy? - The DBT News
CDT’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
Biotech Alert: Searches spiking for these stocks today - TipRanks
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Revolutionizing AI Investment: Why Conduit Pharmaceuticals is a Stock to Watch! - Jomfruland.net
Conduit Pharmaceuticals Inc. (CDT) Advances AI-Driven Drug Development to Phase II - Insider Monkey
Conduit Pharmaceuticals (NASDAQ:CDT) Stock Quotes, Forecast and News Summary - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Dow Dips 400 Points; US Adds Fewer Than Expected Jobs - Benzinga
CDT Stock Price and Chart — NASDAQ:CDT - TradingView
Stock market news: Conduit Pharmaceuticals +103.87%, Doximity +37.47% among top gainers as corporate earnings surpass investor estimates - Business Upturn
Stock market today: Conduit Pharmaceuticals +83.87%, Doximity +31.02% among top gainers as more companies release their quarterly earnings - Business Upturn
Stock Price Rise As Conduit (CDT) Marks Progress In Strategic Alliance - Stocks Telegraph
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development - The Manila Times
Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan
Conduit Pharmaceuticals Inc (CDT) requires closer examination - US Post News
Conduit Pharmaceuticals files to sell 5.9M shares of common stock for holders - MSN
Analysts review Conduit Pharmaceuticals Inc’s rating - Knox Daily
Closing Bell Recap: Conduit Pharmaceuticals Inc (CDT) Ends at 1.80, Reflecting a -18.18 Downturn - The Dwinnex
2.14%
2.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):